title: VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
abstract: BACKGROUND
  VeriStrat(®) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line.
  
  
  METHODS
  Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models.
  
  
  RESULTS
  117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p = 0.0027, HR = 0.480, 95% confidence interval: 0.294-0.784).
  
  
  CONCLUSIONS
  VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.
authors.affiliation: Cantonal Hospital, Luzern, Switzerland. oliver.gautschi@luks.ch
authors.forename: Oliver
authors.initials: O
authors.lastname: Gautschi
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Dingemans
authors.forename: Susanne
authors.initials: S
authors.lastname: Crowe
authors.forename: Solange
authors.initials: S
authors.lastname: Peters
authors.forename: Heinrich
authors.initials: H
authors.lastname: Roder
authors.forename: Julia
authors.initials: J
authors.lastname: Grigorieva
authors.forename: Joanna
authors.initials: J
authors.lastname: Roder
authors.forename: Francesco
authors.initials: F
authors.lastname: Zappa
authors.forename: Miklos
authors.initials: M
authors.lastname: Pless
authors.forename: Martin
authors.initials: M
authors.lastname: Brutsche
authors.forename: Florent
authors.initials: F
authors.lastname: Baty
authors.forename: Lukas
authors.initials: L
authors.lastname: Bubendorf
authors.forename: Shu-Fang
authors.initials: SF
authors.lastname: Hsu Schmitz
authors.forename: Kyung-Jae
authors.initials: KJ
authors.lastname: Na
authors.forename: David
authors.initials: D
authors.lastname: Carbone
authors.forename: Rolf
authors.initials: R
authors.lastname: Stahel
authors.forename: Egbert
authors.initials: E
authors.lastname: Smit
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D054316:Biomarkers, Pharmacological / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000401:mortality*; D017322:Clinical Trials, Phase II as Topic; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011506:Proteins / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D054316:Biomarkers, Pharmacological; D011506:Proteins; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride